Table 1. Baseline characteristics and quality assessment of the Included Studies.
| Study | Age(year) | Patient sex (M/F) | FA | Jadad scale score (6 Items) | Study type | Cases | follow-up (months) |
|---|---|---|---|---|---|---|---|
| Riedl CR 2001 | - | - | 5-ALA | 6 | RCT | 51/51 | - |
| Kriegmair M 2002 | 69.3/69.6 | 53:12/45:19 | 5-ALA | 5 | RCT | 65/64 | - |
| Filbeck T 2002 | 70/68 | - | 5-ALA | 6 | RCT | 88/103 | 21.2/20.5 |
| Babjuk M 2005 | 69.8/67.9 | 39:23/43:17 | 5-ALA | 5 | RCT | 60/62 | 20.7/22.4 |
| Schumacher CM 2010 | 68.9/70.1 | 104:34/103:38 | 5-ALA | 6 | RCT | 138/141 | 12/12 |
| Stenzl A 2011 | - | - | 5-ALA | 7 | RCT | 183/187 | 12/12 |
| Stenzl A 2010 | 68/69.6 | 212:59/223:57 | HAL | 5 | RCT | 271/280 | 12/12 |
| Grossman HB 2012 | |||||||
| Dragoescu.O 2011 | 62/58 | 16:6/18:4 | HAL | 5 | RCT | 22/22 | 9/9 |
| Geavlete B 2012 | - | - | HAL | 7 | RCT | 114/125 | 24/24 |
| Hermann GG 2011 | 69/71 | 58:19/51:17 | HAL | 5 | RCT | 77/68 | 12/12 |
| Karaolides T 2012 | 63.8/66.2 | 40:5/33:8 | HAL | 6 | RCT | 45/41 | 18/18 |
M = male; F = female; 5-ALA = 5-aminolevulinic acid; HAL = hexylaminolaevulinic acid; CIS = carcinoma in situ; FA = fluorescence agent; n = number of patients; RCT = randomized controlled trials.